Krystal Biotech (NASDAQ:KRYS) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $308.70 and traded as low as $281.40. Krystal Biotech shares last traded at $295.90, with a volume of 1,203,533 shares trading hands.

Krystal Biotech News Summary

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter adjusted EPS of $2.05, ahead of analyst estimates ranging from $1.79 to $1.92. Revenue reached $127.34 million, exceeding the $125.77 million consensus estimate and rising approximately 30% year over year. Krystal Biotech Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth was driven by continued strength from Vyjuvek, Krystal’s commercial gene therapy for dystrophic epidermolysis bullosa. Management also announced a $400 million share-repurchase program expected to run over two years, which could support per-share results and signal confidence in the business. Krystal Biotech Beats on Vyjuvek Strength and Adds a Buyback
• Neutral Sentiment: Profitability remains strong, with a reported 54.82% net margin and 19.34% return on equity. However, EPS declined from $2.66 in the year-ago quarter, making continued revenue growth and pipeline execution important for maintaining the stock’s valuation. Krystal Biotech Third-Quarter Earnings Results
• Negative Sentiment: Investors appeared concerned that development timelines for Krystal’s pipeline programs have shifted into 2027. The company also revised its 2026 non-GAAP operating-expense outlook to $155 million-$165 million, raising questions about near-term spending and the timing of additional growth catalysts. Krystal Outlines Buyback and Revises Operating Expense Outlook

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group began coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They set a “buy” rating and a $441.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Royal Bank Of Canada initiated coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 price objective on the stock. Finally, Zacks Research lowered shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research note on Friday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average price target of $377.20.

Krystal Biotech Stock Down 11.0%

The stock has a fifty day moving average of $336.45 and a two-hundred day moving average of $308.70. The stock has a market cap of $8.76 billion, a price-to-earnings ratio of 37.08 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 2nd. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The company had revenue of $127.34 million during the quarter, compared to the consensus estimate of $125.77 million. On average, research analysts expect that Krystal Biotech, Inc. will post 7.33 EPS for the current year.

Insiders Place Their Bets

In other news, Director Dino Rossi sold 25,000 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Heritage Family Offices LLP acquired a new position in shares of Krystal Biotech during the 3rd quarter worth $25,000. Provenance Wealth Advisors LLC purchased a new stake in shares of Krystal Biotech in the 3rd quarter worth about $201,000. Bridge City Capital LLC grew its stake in Krystal Biotech by 21.9% in the 3rd quarter. Bridge City Capital LLC now owns 14,404 shares of the company’s stock valued at $4,790,000 after acquiring an additional 2,588 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Krystal Biotech in the 3rd quarter valued at about $503,000. Finally, Profund Advisors LLC grew its stake in Krystal Biotech by 26.7% in the 3rd quarter. Profund Advisors LLC now owns 7,313 shares of the company’s stock valued at $2,432,000 after acquiring an additional 1,543 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.